| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 |
| filingDate |
2003-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcc28b04fb1f76143dfeb7606f184f7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a58b2ecbc44541e56ce824699c07756
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2dabd655e713f27de517b2475a68eb8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1075a2e5f17fe2b30f75da3aeb94c81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07c826923aafe465e981221c6bae6e87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2373040b74b0440275a2a8a8cfedd2c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_191266130428cf94ab14fafed7717b88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3da32dfbecdd45725d2391913c557c33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d74dbb46dcf7f6148ae7756f4438010 |
| publicationDate |
2004-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1469863-A2 |
| titleOfInvention |
Selective s1p1/edg1 receptor agonists |
| abstract |
The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Pharmaceutical compositions are included. The invention also encompasses a method of identifying candidate compounds that are agonists of the S1P1/Edg1 receptor and which possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor. The invention further encompasses a method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said respiratory disease or condition, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor. |
| priorityDate |
2002-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |